HOME >> BIOLOGY >> NEWS
Breast cancer is multi-step, multi-cell type process

COLUMBUS, Ohio -Researchers at The Ohio State University Comprehensive Cancer Center are offering one of the first models of breast cancer as a multi-step process which involves more than one cell type, thanks in part to new laser-microdissection technology which enables them to take apart tumors one cell at a time.

Scientists know cancer develops over a period of years through a series of genetic changes or mutations. Scientists have also long accepted that these genetic mutations occur in a single cell type for any given cancer. But the sequence of events-which "hits" happen first, and which specific cells are involved-has not been clearly documented until now.

Writing in the September 1 issue of Human Molecular Genetics, a research team, led by Dr. Charis Eng, director of the Clinical Cancer Genetics Program at Ohio State, says it has uncovered evidence suggesting that genetic changes leading to breast cancer occur first in the epithelium of breast tissue, and then are followed by corresponding alterations in the surrounding structures, or stroma.

"This is almost paradigm-breaking," says Eng. "In breast cancer, the alterations that lead to malignancy are thought to occur only in the epithelial cells of the breast. We have shown for the first time that genetic mutations can occur with some frequency in the stromal cells, too."

Utilizing laser capture microdissection, (LCM) investigators examined the tissue of 41 invasive breast cancers. In LCM technology, a laser beam only 7.5 microns in width - roughly one-tenth the size of a human hair -- acts as a "knife"- enabling researchers to isolate cancerous cells from normal cells, and to separate epithelial cells from stromal cells.

"Before LCM, the study of cancer genetics entailed grinding up a lump of tumor comprising a mixture of cells and examining the 'mixed bag' of cells for gene alterations," says Eng. "We really couldn't attribute genetic changes to any one cell type. LCM allo
'"/>

Contact: Michelle Gailiun
gailiun.1@osu.edu
614-293-3737
Ohio State University Medical Center
1-Sep-2001


Page: 1 2

Related biology news :

1. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
2. Breastfeeding decreases infant mortality
3. Breast cancer study suggests role for tissue in carcinogenesis
4. Breast self examination increases womens concerns but has no effect on mortality
5. Breast cancer follow-ups no longer guess-work thanks to new physics research
6. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
7. The 4th European Breast Cancer Conference (EBCC4)
8. Breast cancer susceptibility genes play role in DNA repair
9. Breast cancer can be reversed in laboratory mice, scientists report
10. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
11. Breast fluid a better option for detecting cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
Breaking Biology Technology:
Cached News: